Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo, moxifloxacin, electrocardiogram (ECG); Drug · Procedure
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: crizotinib, ketoconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions: ASTX727, Dacogen; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 39
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Mucociliary Clearance
Interventions: HFO-1234ze(E), HFA-134a; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Kansas City, Kansas • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more

Conditions: Visual Acuity
Interventions: JJVC Investigational Multifocal Contact Lenses, Dailies Total 1® Multifocal Contact Lenses; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 12
States / cities: Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 8 more

Conditions: Acute Myeloid Leukemia
Interventions: Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT); Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more

Conditions: Relapsed or Refractory Lymphoma
Interventions: HMPL-523, Rabeprazole; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Subjects
Interventions: Metformin 500 mg Oral Tablet, Levoketoconazole 150 - 600 mg (BID); Drug
Lead sponsor: Cortendo AB; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Disease, Chronic Obstructive, COPD
Interventions: Ensifentrine, Placebo, LABA/LAMA; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: ALXN1840, Placebo, Moxifloxacin; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Visual Acuity
Interventions: EMO-200, EMO-118; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 7 Years to 12 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Major Fetal Anomaly
Interventions: Whole Genome Sequencing, Amniocentesis, Psychosocial assessment; Genetic · Procedure · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Medullary Thyroid Cancer, Colon Cancer
Interventions: Tumor Genomic Analysis; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Overweight, Obesity, Craving, Eating Behavior
Interventions: Retrieval-extinction (R-E) Training, Extinction Training; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 59 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers
Interventions: PF-04449913, ketoconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alpha-Gal Syndrome, Allergy
Interventions: DBFC with 150g of Alpha-gal Knock Out (KO) pork, DBFC with 150g of Wild Type (WT) pork; Diagnostic Test
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 50 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Little Rock, Arkansas • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Impulse Control Disorder, Parkinson Disease
Interventions: rTMS Active, rTMS Sham; Device
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Substance-Related Disorders
Interventions: Palonosetron, Hydroxyzine, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Parkinson's Disease
Interventions: XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more

Conditions: Healthy
Interventions: crizotinib, rifampin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Healthy Volunteer
Interventions: BIIB145, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Maribavir; Drug
Lead sponsor: Takeda; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants

Comparison of a Silicone Hydrogel Daily Disposable Multifocal Contact Lens to a Marketed Product

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

HMPL-523 Food Effect and Proton Pump Inhibitor Study

Drug Interaction Study of Levoketoconazole and Metformin

Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Evaluating Visual Acuity and Initial Fit Performance of Two Soft Contact Lenses

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Development of an Optimal Approach to Return of Results for Next-generation Sequencing for Prenatal Diagnosis

Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer

Memory-Updating Technique to Reduce Food Craving and High Calorie Food Intake Among Individuals With Overweight/Obesity

Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels

Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects

Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

Maribavir Food-Effect Study in Healthy Adults Participants